Related Experiment Videos
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
C W Reuter1, M A Morgan, L Bergmann
1Department of Internal Medicine III (Hematology and Oncology), University of Ulm, Ulm, Germany. christoph.reuter@medizin.uni-ulm.de
Abstract:
A series of alterations in the cellular genome affecting the expression or function of genes controlling cell growth and differentiation is considered to be the main cause of cancer. These mutational events include activation of oncogenes and inactivation of tumor suppressor genes. The elucidation of human cancer at the molecular level allows the design of rational, mechanism-based therapeutic agents that antagonize the specific activity of biochemical processes that are essential to the malignant phenotype of cancer cells. Because the frequency of RAS mutations is among the highest for any gene in human cancers, development of inhibitors of the Ras-mitogen-activated protein kinase pathway as potential anticancer agents is a very promising pharmacologic strategy. Inhibitors of Ras signaling have been shown to revert Ras-dependent transformation and cause regression of Ras-dependent tumors in animal models. The most promising new class of these potential cancer therapeutics are the farnesyltransferase inhibitors. The development of these compounds has been driven by the observation that oncogenic Ras function is dependent upon posttranslational modification, which enables membrane binding. In contrast to many conventional chemotherapeutics, farnesyltransferase inhibitors are remarkably specific and have been demonstrated to cause no gross systemic toxicity in animals. Some orally bioavailable inhibitors are presently being evaluated in phase II clinical trials. This review presents an overview on some inhibitors of the Ras signaling pathway, including their specificity and effectiveness in vivo. Because Ras signaling plays a crucial role in the pathogenesis of some hematologic malignancies, the potential therapeutic usefulness of these inhibitors is discussed. (Blood. 2000;96:1655-1669)
Insights
Targeting the Ras signaling pathway with farnesyltransferase inhibitors shows promise for cancer treatment. These specific agents demonstrate effectiveness in preclinical models with minimal toxicity, advancing to clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer arises from genomic alterations, including oncogene activation and tumor suppressor gene inactivation.
- Molecular understanding of cancer enables targeted therapies against malignant cell processes.
- RAS mutations are frequent in human cancers, making the Ras-mitogen-activated protein kinase pathway a key therapeutic target.
Purpose of the Study:
- To review inhibitors of the Ras signaling pathway as potential anticancer agents.
- To discuss the specificity and in vivo effectiveness of these inhibitors.
- To explore the therapeutic potential of Ras pathway inhibitors in hematologic malignancies.
Main Methods:
- Review of existing literature on Ras signaling pathway inhibitors.
- Analysis of preclinical data on Ras pathway inhibitors, including farnesyltransferase inhibitors.
- Evaluation of clinical trial data for orally bioavailable inhibitors.
Main Results:
- Inhibitors of Ras signaling can revert Ras-dependent transformation and reduce tumor growth in animal models.
- Farnesyltransferase inhibitors, targeting Ras posttranslational modification, show high specificity and low systemic toxicity in animals.
- Several orally bioavailable inhibitors are currently in phase II clinical trials.
Conclusions:
- Inhibitors of the Ras signaling pathway, particularly farnesyltransferase inhibitors, represent a promising class of targeted cancer therapeutics.
- The specificity and favorable toxicity profile of these agents warrant further clinical investigation.
- Ras pathway inhibitors hold potential for treating hematologic malignancies due to Ras signaling's role in their pathogenesis.